Agree with LZ, sequencing cost may not be a problem in the future. PacBio claims to sequence the human genome with $100, GnuBio claims $30 in the future. What will be the biggest problems are data analysis and interpretation. A regular lab probably won't have the computing resources for whole genome analysis, so people are talking about cloud computing and offer a genome browser interface for users, like DNAnexus. Interpretation is also a formidable task. There will be so many variants with un
【在 w******a 的大作中提到】 : Agree with LZ, sequencing cost may not be a problem in the future. PacBio : claims to sequence the human genome with $100, GnuBio claims $30 in the : future. What will be the biggest problems are data analysis and : interpretation. A regular lab probably won't have the computing resources : for whole genome analysis, so people are talking about cloud computing and : offer a genome browser interface for users, like DNAnexus. Interpretation : is also a formidable task. There will be so many variants with un
I believe that the data analysis play a very important role in the next- generation sequencer. As i mentioned that a pathologist do not want to waste time in reading sequence results. I am thinking if hundreds of thousands of sequence results were automatically analysed before they go to a pathologist. Pathologist only need to pick up the final mutant results and screen the one related to targeted therapy. That need somebody to put all the normal sequence, SNP and mutation information into the d
【在 L******e 的大作中提到】 : I believe that the data analysis play a very important role in the next- : generation sequencer. As i mentioned that a pathologist do not want to waste : time in reading sequence results. I am thinking if hundreds of thousands of : sequence results were automatically analysed before they go to a : pathologist. Pathologist only need to pick up the final mutant results and : screen the one related to targeted therapy. : That need somebody to put all the normal sequence, SNP and mutation : information into the d
NGS has higher error rate than Sanger, however, the deep sequencing (high coverage) is capable of improving it. As matter of fact, a few private companies already provide "personal sequencing", which is used by physicians as reference for prescriptions (personal drugs). FDA actually is trying hard to regulate these services by, for example, implementing "prescription needed" policy for the service providers when customers knock at the doors. Here comes an interesting question: what kinda physic